NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage biotech company and majority-owned subsidiary of SciSparc Ltd., announced the launch of its Phase IIb clinical trial site at the Yale Child Study Center, Yale School of Medicine, in New Haven, Connecticut. This U.S. site is part of a global development program for SCI-110, the company's proprietary cannabinoid-based drug candidate designed to treat Tourette Syndrome (TS) in adults. The trial is led by Dr. Michael H. Bloch and represents a pivotal step in advancing a treatment for a condition with limited therapeutic options.
The Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial evaluating the efficacy, safety, and tolerability of daily oral SCI-110 in patients aged 18 to 65. SCI-110 combines dronabinol with palmitoylethanolamide in a single dosage form, aiming to reduce tics and associated comorbid symptoms while minimizing side effects. The primary endpoint is the change in tic severity measured by the Yale Global Tic Severity Scale (YGTSS) at weeks 12 and 26 compared to baseline. This follows the positive results from the Phase IIa study, which demonstrated an average tic reduction of 21% across participants, as measured by the same gold-standard scale.
In addition to the Yale site, the trial is underway at Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel. This international collaboration underscores the global need for effective TS treatments. Dr. Adi Zuloff-Shani, Chief Technology Officer of NeuroThera, highlighted the significance of the U.S. launch: "Launching a U.S. site at the Yale Child Study Center represents a significant milestone in our global development program for SCI-110. TS remains a major unmet medical need with limited therapeutic options, particularly in adults who continue to experience persistent, severe, and often debilitating symptoms."
The initiation of the trial at Yale is crucial for several reasons. First, it expands the geographic reach of the study, enhancing patient recruitment and diversity. Second, the Yale Child Study Center is renowned for its expertise in tic disorders, adding credibility to the trial's execution. Third, this development brings hope to the estimated 0.5% of the population affected by TS, many of whom have not found adequate relief from existing treatments, which are often antipsychotics with significant side effects.
For NeuroThera, advancing SCI-110 through clinical trials is a strategic move to address a niche but underserved market. If successful, SCI-110 could become the first cannabinoid-based treatment specifically approved for TS, offering a new mechanism of action that may improve patient outcomes. The company's commitment to rigorous clinical evaluation is evident in its adherence to established endpoints and safety monitoring.
The announcement also reflects a broader trend in psychiatric research: exploring the therapeutic potential of cannabinoids for neurological and psychiatric disorders. As the scientific community continues to uncover the role of the endocannabinoid system in motor control and emotional regulation, compounds like SCI-110 represent a promising frontier. However, the path to regulatory approval is long and fraught with challenges, including the need to demonstrate consistent efficacy and safety across diverse populations.
With the trial now active at multiple international sites, NeuroThera is poised to generate robust data that could support future regulatory filings. The company's forward-looking statements caution that outcomes are not guaranteed, but the initiation at a prestigious institution like Yale signals confidence in the drug's potential. For patients and clinicians alike, this development is a beacon of hope in a field where innovation has been slow.
The implications of this trial extend beyond TS. The insights gained from SCI-110 could inform the development of other cannabinoid-based therapies for conditions such as chronic pain, anxiety, and movement disorders. By leveraging the endocannabinoid system, researchers may unlock new treatment paradigms that are more targeted and tolerable than existing options.
As the Phase IIb trial progresses, stakeholders will eagerly await interim results. The collaboration between NeuroThera, Yale, and other international centers exemplifies the power of global partnerships in advancing medical science. While challenges remain, the initiation of this trial marks a significant stride toward addressing the unmet needs of adults living with Tourette syndrome.
